scholarly journals Interleukin-28B genotypes determine response to pegylated-interferon plus ribavirin therapy in patients with hepatitis C virus infection

2011 ◽  
Author(s):  
Akira Andoh
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Virus Infection ◽  
Pegylated Interferon ◽  
Hepatitis C Virus Infection ◽  
Interleukin 28B ◽  
Pegylated Interferon Plus Ribavirin

scholarly journals Hepatitis C Virus Infection and Dialysis: 2012 Update

2013 ◽  
Vol 2013 ◽  
pp. 1-11 ◽  
Author(s):  
Fabrizio Fabrizi
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Virus Infection ◽  
Antiviral Treatment ◽  
Sustained Viral Response ◽  
Pegylated Interferon ◽  
Hepatitis C Virus Infection ◽  
Dialysis Patients ◽  
Increased Risk ◽  
Pegylated Interferon Plus Ribavirin

Hepatitis C virus infection is still common among dialysis patients, but the natural history of HCV in this group is not completely understood. Recent evidence has been accumulated showing that anti-HCV positive serologic status is significantly associated with lower survival in dialysis population; an increased risk of liver and cardiovascular disease-related mortality compared with anti-HCV negative subjects has been found. According to a novel meta-analysis (fourteen studies including 145,608 unique patients), the adjusted RR for liver disease-related death and cardiovascular mortality was 3.82 (95% CI, 1.92; 7.61) and 1.26 (95% CI, 1.10; 1.45), respectively. It has been suggested that the decision to treat HCV in patients with chronic kidney disease be based on the potential benefits and risks of therapy, including life expectancy, candidacy for kidney transplant, and co-morbidities. According to recent guidelines, the antiviral treatment of choice in HCV-infected patients on dialysis is mono-therapy but fresh data suggest the use of modern antiviral approaches (i.e., pegylated interferon plus ribavirin). The summary estimate for sustained viral response and drop-out rate was 56% (95% CI, 28–84) and 25% (95% CI, 10–40) in a pooled analysis including 151 dialysis patients on combination antiviral therapy (conventional or pegylated interferon plus ribavirin).

Factor VIII and IX deficiencies related to acquired inhibitors in a patient with chronic hepatitis C virus infection receiving treatment with pegylated interferon plus ribavirin

Hematology ◽  
2011 ◽  
Vol 16 (2) ◽  
pp. 80-85 ◽  
Author(s):  
Marilza Campos‐de‐Magalhães ◽  
Carlos Eduardo Brandão‐Mello ◽  
Maria Lúcia Elias Pires ◽  
Maria Cecília da Fonseca Salgado ◽  
Selma Barcelo de Brito ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Virus Infection ◽  
Factor Viii ◽  
Pegylated Interferon ◽  
Hepatitis C Virus Infection ◽  
Pegylated Interferon Plus Ribavirin ◽  
Chronic Hepatitis C Virus ◽  
Viii And Ix

scholarly journals Quantification of Different Human Alpha Interferon Subtypes and Pegylated Interferon Activities by Measuring MxA Promoter Activation

2005 ◽  
Vol 49 (9) ◽  
pp. 3770-3775 ◽  
Author(s):  
Catherine François ◽  
Isabelle Bernard ◽  
Sandrine Castelain ◽  
Bryan Charleston ◽  
Martin D. Fray ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Virus Infection ◽  
Biological Samples ◽  
Pegylated Interferon ◽  
Biologically Active ◽  
Enzyme Linked Immunosorbent Assay ◽  
Hepatitis C Virus Infection ◽  
Promoter Activation ◽  
Antiviral Protein

ABSTRACT Alpha interferons (α-IFNs) are potent biologically active proteins synthesized and secreted by somatic cells during viral infection. Quantification of α-IFN concentrations in biological samples is used for diagnosis. More recently, recombinant IFNs have been used as antiviral, antiproliferative, and immunomodulatory therapeutic agents, and particularly for the treatment of chronic hepatitis C virus infection. For this purpose, IFN has recently been coupled to polyethylene glycol (PEG) to improve the pharmacokinetic properties. The measure of α-IFN in biological samples from treated patients could be useful to ensure compliance to therapy and the true IFN activity in relation to viral decay during follow-up. In particular, it could be used to monitor the PEG-IFN concentration in patients treated for hepatitis C virus infection. The most frequently used test is a bioassay based on the antiviral property of the IFN, but the assay is not highly reproducible. Here, we present a reporter test based on MxA promoter activation of chloramphenicol acetyltransferase expression (Mx-CAT). MxA is an antiviral protein induced and tightly regulated by α-IFN. The Mx-CAT assay showed good reproducibility of 15% and was suitable to quantify PEG-IFN and numerous other α-IFN subtypes as well, despite a differential MxA promoter activation in relation with the subtype. A good correlation was obtained with the reporter assay and a commercial enzyme-linked immunosorbent assay on samples from treated patients. This test could be useful for monitoring IFN therapy of chronically infected hepatitis C virus-infected patients treated with the standard IFN, PEG-IFN, and probably forthcoming recombinant IFNs.

Sign in / Sign up

Export Citation Format

Share Document